

Human Leuprolide - Purified

| | |
|--------------------------|---|
| Catalog No.: | PA1191XC |
| Quantity: | 0.1 g |
| Concentration: | 1.0 mg/ml |
| Species: | Human |
| Source: | Synthetic |
| Format: | State: Sterile Filtered White lyophilized (freeze-dried) powder. Purity: >98% Greater than 98.0% as determined by: (a) Analysis by RP-HPLC, (b) Mass Spectral Analysis {MALDI-TOF exhibits correct Mw}. Buffer System: Lyophilized from a concentrated solution in water containing no additives. Reconstitution: It is recommended to reconstitute the lyophilized Leuprolide in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions. |
| Description: | Synthetic Human Leuprolide is a single, non-glycosylated, polypeptide chain containing 9 amino acids and having a molecular mass of. The b chain has an N-glycosilation site and its structure and glycosilation pattern are very similar to that of pituitary LHRH. AA Sequence: Glu-His-Trp-Ser-Tyr-DLeu-Leu-Arg-Pro-NH ₂ . Molecular weight: 1 kDa 1209 Dalton |
| Storage: | Lyophilized Leuprolide although stable at room temperature for 3 weeks, should be stored desiccated below -18°C. Upon reconstitution Leuprolide should be stored at 4°C between 2-7 days and for future use below -18°C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles. |
| General Readings: | <ol style="list-style-type: none">1. Chalmers LJ, Casas L, New MI, Blackett PR. Prolongation of growth by treatment of 11-hydroxylase deficiency with depot-leuprolide, growth hormone, and hydrocortisone. <i>J Pediatr Endocrinol Metab.</i> 2006 Oct;19(10):1251-5. PubMed PMID: 17172087.2. Re: Olav Erich Yri, Trine Bjoro and Sophie D. Fossa. Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer. <i>Eur urol</i> 2006;49:54-8. <i>Eur Urol</i> 2007 Apr;51(4):11463. Mericq G MV, Youlton R R, Willshaw Z ME. [Effectiveness of Leuprolide acetate therapy every three months in central precocious puberty]. <i>Rev Med Chil.</i> 2006 Jul;134(7):821-6. Epub 2006 Aug 29. PubMed PMID: 17130963.4. Gustofson RL, Segars JH, Larsen FW. Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome. <i>Hum Reprod.</i> 2006 Nov;21(11):2830-7. Epub 2006 Sep 11. PubMed PMID: 16966348.5. Stability of poly(D,L-lactide-co-glycolide) and leuprolide acetate in in-situ forming drug |

delivery systems. J Control Release 2006 Oct 10;115(2):158-67
 6. Singh S, Singh J. Phase-sensitive polymer-based controlled delivery systems of leuprolide acetate: in vitro release, biocompatibility, and in vivo absorption in rabbits. Int J Pharm. 2007 Jan 2;328(1):42-8. Epub 2006 Aug 1. PubMed PMID: 16959451.

Pictures:

Precursor- Protein structure and amino acid sequence

